Ypsomed launches new reusable ServoPen® in China

Burgdorf, (PresseBox) - Ypsomed launches its newly developed reusable ServoPen® insulin pen for the first time in China together with its long-time customer Tonghua Dongbao Pharmaceutical Co., Ltd. a leading pharmaceutical company and insulin manufacturer in China. The ServoPen® is Ypsomed's most advanced insulin pen, which has been awarded the internationally acclaimed reddot design award 2010.

Tonghua Dongbao Pharmaceutical Co., Ltd. to sell the ServoPen® in China

Starting in the fourth quarter 2010, the ServoPen® reusable insulin pen system will be sold in China under the brand name "Gansulin® Pen" together with the insulin Gansulin® exclusively by the leading Chinese pharmaceutical com-pany Tonghua Dongbao Pharmaceutical Co.,Ltd.. Ypsomed's CEO Richard Fritschi is extremely pleased about the extension of the partnership with Tonghua Dongbao: "China is a large and strongly growing diabetes and insulin market. Ypsomed is very proud to extend the long-lasting relationship with Tonghua Dongbao Pharmaceutical Co.,Ltd., one of the leading local insulin providers in China. As one of the first Swiss medtec companies, Ypsomed has successfully been audited according to ISO 13485 standards by the State Food and Drug Administration (SFDA) of the P.R. of China." Tonghua Dongbao has been working with Ypsomed since 2006 when they launched the Ypsopen®, Ypsomed's tried-and-tested, user-friendly reusable insulin pen. Yikui Li, Chairman and & President of Dongbao Enterprise Group Co., Ltd. is equally excited: "With the Gansulin® Pen developed by our innovative partner Ypsomed from Switzerland, Tonghua Dongbao will bring the best reusable insulin pen on the market and contribute with a top-quality Swiss product to improve the lives of millions of people with diabetes in China."

Large and strongly growing insulin market in China

Current estimates suggest that there are more than 90 million individuals with diabetes in China. In comparison, just approximately 25 million individuals in the US and approximately 50 million individuals in India are estimated to have diabetes - these include undiagnosed patients. In particular, it is expected that the insulin market will see high growth in China in upcoming years with estimates ranging from 25% to 30% annually. This strong growth is mainly driven by sales of human insulin, which currently has an estimated 80% market share. The company Dongbao Enterprise Group (www.thdb.com) was founded in 1985 and has, thanks to high investments in research and development, grown to be one of the leading pharmaceutical manufacturers in China with twenty subsidiaries. As manufacturer of active pharmaceutical ingredients (APIs), the company holds numerous patents and provides medication, especially human insulin, to millions of people in China and Asia.

ServoPen® - The most advanced reusable insulin pen in the market

Ypsomed's most recently developed reusable ServoPen® insulin pen has been awarded the internationally acclaimed red dot design award 2010. The ServoPen® is innovative and impresses with its user-oriented design and improved functionality. The ServoPen® is a high-quality, reusable insulin pen with a spring-assisted injection mechanism and a robust yet lightweight multi-colored aluminum casing. Technical advantages including the spring-assisted delivery (less force and shorter injection stroke distance), effortless cartridge exchange via the bayonet connection, a retractable piston rod for ease of use, an easy-to-grip dose function with resultant easy dose dialing, optional dose-correction and dose-interruption functions, as well as durability and interchangeable insulin color rings simplify daily use and give the user the safety required. With the ServoPen®, Ypsomed sets a new standard in insulin medication, in terms of patient comfort and user-friendliness.

Ypsomed AG

The Ypsomed Group is a leading independent developer and manufacturer of injection systems for self-medication and a well-known diabetes specialist with more than 25 years' experience. The Ypsomed Group, which emerged in 2003 from the Disetronic Group, offers insulin pumps, injection systems and pen needles for diabetes, growth hormone and infertility treatments as well as for other therapeutic purposes. Ypsomed is an innovation and technology leader with an extensive patent portfolio and is the preferred partner of pharmaceutical and biotech companies in the self-medication sector. The Ypsomed Group has its headquarters in Burgdorf, Switzerland. It has several manufacturing sites in Switzerland as well as leading independent diabetes product sales companies throughout Europe. The Ypsomed Group employs approximately 1'150 employees.

Diese Pressemitteilungen könnten Sie auch interessieren

News abonnieren

Mit dem Aboservice der PresseBox, erhalten Sie tagesaktuell und zu einer gewünschten Zeit, relevante Presseinformationen aus Themengebieten, die für Sie interessant sind. Für die Zusendung der gewünschten Pressemeldungen, geben Sie bitte Ihre E-Mail-Adresse ein.

Es ist ein Fehler aufgetreten!

Vielen Dank! Sie erhalten in Kürze eine Bestätigungsemail.

Ich möchte die kostenlose Pressemail abonnieren und habe die Bedingungen hierzu gelesen und akzeptiert.